Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to ‌protect against Bundibugyo ebolavirus, a strain of Ebola that has ‌killed more than 1,650 people so far and currently has no approved vaccine. Health Canada ​has cleared an early-stage study and the first volunteers have already received the shot, called mRNA-1469, acording to the vaccine maker. The experimental shot uses the same mRNA technology behind Moderna's COVID-19 vaccine. The trial, ‌which will run at ⁠three sites in Canada, aims to enroll about 80 healthy adults to check if the vaccine is ⁠safe and triggers an immune response. The World Health Organization ​and Africa CDC ​have both declared the current outbreak a public health emergency.